Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua B. Cohen Sells 21,490 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $74,570.30. Following the completion of the transaction, the chief executive officer now directly owns 3,355,280 shares of the company’s stock, valued at approximately $11,642,821.60. The trade was a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Stock Down 2.3 %

AMLX opened at $3.43 on Friday. The business has a fifty day moving average of $3.55 and a 200 day moving average of $4.05. The stock has a market cap of $303.90 million, a P/E ratio of -0.90 and a beta of -0.51. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. Equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $7.33.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AMLX. Boxer Capital Management LLC purchased a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth approximately $6,615,000. Bank of America Corp DE increased its holdings in Amylyx Pharmaceuticals by 165.9% during the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company’s stock worth $9,171,000 after purchasing an additional 1,513,748 shares during the period. Walleye Capital LLC raised its position in Amylyx Pharmaceuticals by 986.5% during the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after purchasing an additional 608,874 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Amylyx Pharmaceuticals by 862.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company’s stock worth $1,786,000 after buying an additional 423,316 shares during the period. Finally, Jane Street Group LLC grew its position in shares of Amylyx Pharmaceuticals by 122.4% during the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company’s stock worth $2,893,000 after buying an additional 421,302 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.